Stratview Research has published a new report on the Chronic Idiopathic Constipation (CIC) Drugs Market, segmented By Product Type (Lubiprostone, Linaclotide, Others), End-User (Hospitals & Clinics, Ambulatory Surgical Centres, Long Term Care Centres, Others), and Region.
This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global artificial intelligence as a service market.
Market Highlights
The Chronic Idiopathic Constipation (CIC) Drugs market is projected to grow from USD 4.1 billion in 2020 to USD 6.0 billion by 2026 at a CAGR of around 6.8% during the forecast period.
To know more about the covid impact on the market, click here: https://www.stratviewresearch.com/Request-Sample/2406/Chronic-Idiopathic-Constipation-(CIC)-Drugs-Market.html#form
Covid Impact
Covid-19 has impacted the market dynamics, competition, and global supply chain of every possible market one can think of. The revenues for many, have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operations and strategy will sustain and beat the competition.
Segmentation –
This report studies the Chronic Idiopathic Constipation (CIC) Drugs Market and has segmented the market in a few ways, keeping in mind the concentration of all the stakeholders across the value chain. Following are the ways in which the market has been segmented in the report:
By end-user, the chronic idiopathic constipation (CIC) drugs market has been bifurcated into hospitals & clinics, ambulatory surgical centers, long-term care centers, and others. Under these, the hospitals & clinics segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period.
By region, the market in North America accounted for the largest market share in 2020 and is projected to grow at a significant CAGR during the assessment period. The regional growth is primarily attributed to the high prevalence of chronic constipation particularly among the geriatric populace coupled with the presence of key market players such as Actavis Generics (US) and Pfizer Inc. (US). The market growth in the Asia-Pacific region is expected to be driven by rising awareness among consumers regarding CIC drugs coupled with the rising geriatric population in developing countries, particularly China and India.
Following are the key players in the Chronic Idiopathic Constipation (CIC) Drugs Market:
· Actavis Generics (US)
· The Chugai Pharmaceutical Co., Ltd (Japan)
· Ferring International Center, S.A. (Switzerland)
· Synergy Pharmaceuticals (US)
· Pfizer Inc. (US)
· GlaxoSmithKline plc (UK)
· F. Hoffmann-La Roche AG (Switzerland)
· Sanofi S.A. (France)
· Bayer AG (Germany)
· Salix Pharmaceuticals, Inc. (US)
· Sucampo Pharmaceuticals, Inc. (US)
· Ironwood Pharmaceuticals, Inc (US)
· Progenics Pharmaceuticals, Inc. (US).
About Stratview Research-
Stratview Research is a global market intelligence firm having a strong team of industry veterans and research analysts. Stratview Research has been serving multiple clients across a wide array of industries. Our services cover a broad spectrum of industries including but not limited to Energy Chemicals, Advanced Materials, Automotive, and Aerospace. At Stratview, we believe in building long term relations with our clients.
Connect with our team here–
https://www.stratviewresearch.com/contact
Or
Call us @: +1-313-307-4176
Write a comment